Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Egeberg

Showing results (1-10 of 331) with videos related to

Pageof 34
Sort By:
The New England Journal of Medicine|December 14, 2016
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque PsoriasisAlexander Egeberg
Danish Medical Journal|February 3, 2016
Psoriasis and comorbidities. Epidemiological studiesAlexander Egeberg
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine|July 25, 2016
Effect of Biological Therapy on the Risk of Sleep Apnea in Patients with PsoriasisAlexander Egeberg, Lone Skov
Expert Opinion on Pharmacotherapy|May 19, 2016
Management of cardiovascular disease in patients with psoriasisAlexander Egeberg, Lone Skov
The Journal of Dermatological Treatment|April 28, 2022
Killing all the birds with one drug - is oral roflumilast a novel treatment option for psoriasis?Mette Gyldenløve, Alexander Egeberg
The Journal of Rheumatology|November 2, 2021
Is Real-world Evidence Really Real?Lars Erik Kristensen, Alexander Egeberg
JAMA Neurology|July 26, 2016
Association Between Rosacea and Parkinson Disease-ReplyAlexander Egeberg, Jacob P Thyssen
The New England Journal of Medicine|January 12, 2018
Canakinumab for Atherosclerotic DiseaseKasper F Hjuler, Alexander Egeberg
Journal of the American Academy of Dermatology|June 17, 2019
Factors associated with patient-reported importance of skin clearance among adults with psoriasis and atopic dermatitisAlexander Egeberg, Jacob P Thyssen
The British Journal of Dermatology|February 17, 2023
Increased reporting of cerebrovascular accidents with use of risankizumab observed in the Food and Drug Administration Adverse Events Reporting System (FAERS)Alexander Egeberg, Jacob P Thyssen
Pageof 34

Showing results (1-10 of 331) with videos related to

Sort By:
Pageof 34
The New England Journal of Medicine|December 14, 2016
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque PsoriasisAlexander Egeberg
Danish Medical Journal|February 3, 2016
Psoriasis and comorbidities. Epidemiological studiesAlexander Egeberg
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine|July 25, 2016
Effect of Biological Therapy on the Risk of Sleep Apnea in Patients with PsoriasisAlexander Egeberg, Lone Skov
Expert Opinion on Pharmacotherapy|May 19, 2016
Management of cardiovascular disease in patients with psoriasisAlexander Egeberg, Lone Skov
The Journal of Dermatological Treatment|April 28, 2022
Killing all the birds with one drug - is oral roflumilast a novel treatment option for psoriasis?Mette Gyldenløve, Alexander Egeberg
The Journal of Rheumatology|November 2, 2021
Is Real-world Evidence Really Real?Lars Erik Kristensen, Alexander Egeberg
JAMA Neurology|July 26, 2016
Association Between Rosacea and Parkinson Disease-ReplyAlexander Egeberg, Jacob P Thyssen
The New England Journal of Medicine|January 12, 2018
Canakinumab for Atherosclerotic DiseaseKasper F Hjuler, Alexander Egeberg
Journal of the American Academy of Dermatology|June 17, 2019
Factors associated with patient-reported importance of skin clearance among adults with psoriasis and atopic dermatitisAlexander Egeberg, Jacob P Thyssen
The British Journal of Dermatology|February 17, 2023
Increased reporting of cerebrovascular accidents with use of risankizumab observed in the Food and Drug Administration Adverse Events Reporting System (FAERS)Alexander Egeberg, Jacob P Thyssen
Pageof 34